• Exchange: SIX Swiss Ex
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

ATLN:VX

118.200 CHF 0.900 0.77%

As of 11:30:15 ET on 12/19/2014.

Snapshot for Actelion Ltd (ATLN)

Open: 119.000 Day's Range: 117.200 - 119.500 Volume: 878,024
Previous Close: 117.300 52wk Range: 73.149 - 119.500 1-Yr Rtn: +61.53%

Stock Chart for ATLN

No chart data available.
  • ATLN:VX 118.200
  • 1D
  • 1M
  • 1Y
117.300
Interactive ATLN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for ATLN

Current P/E Ratio (ttm) 18.4112
Estimated P/E(12/2014) 20.6391
Relative P/E vs. SMI 0.9377
Earnings Per Share (CHF) (ttm) 6.4200
Est. EPS (CHF) (12/2014) 5.7270
Est. PEG Ratio 2.0801
Market Cap (M CHF) 13,489.98
Shares Outstanding (M) 114.13
30 Day Average Volume 384,976
Price/Book (mrq) 6.7175
Price/Sale (ttm) 6.7416
Dividend Indicated Gross Yield 1.02%
Cash Dividend (CHF) 1.2000
Dividend Ex-Date 05/12/2014
5 Year Dividend Growth -
Next Earnings Announcement 02/16/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for ATLN

  • Revenue
  • Net Income (M/CHF)
  • Profit Margin (%)

Company Profile & Key Executives for ATLN

Actelion Ltd. is a pharmaceutical company that develops and markets synthetic small-molecule drugs against diseases related to the endothelium. The Company's drugs, Veletri and Tracleer, are used in the treatment of heart and pulmonary conditions.

Jean-Paul ClozelCEO/Co-FounderAndre C MullerChief Financial Officer
Otto SchwarzExec VP/COOGuy BraunsteinExec VP/Head:Clinical Dev
More Company Profile & Key Executives for ATLN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil